2015 REVIEW: Japan - Corporate Rejigs, Generic Explosions, Regulatory Advances
This article was originally published in PharmAsia News
If you missed any of our major news and analysis from Japan in 2015, here's an opportunity to check out PharmAsia News's pick of the most important stories of the year, ranging from key regulatory initiatives to company restructuring to new generic competition for local blockbusters.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.